reproxalap
Small Molecule Target: RASP
Aldeyra Therapeutics, Inc.
Most recent annual filing: 2026-02-15
Pipeline (8 active programs)
ADX-2191
ADX-248
Small Molecule Target: RASP
- Atopic Dermatitis
- Undisclosed indication
ADX-246
Small Molecule Target: RASP
- Age-Related Macular Degeneration
- Undisclosed indication
Technology platforms
RASP Modulator Platform
Platform of small molecule reactive aldehyde species (RASP) modulators that covalently bind and deplete RASP, modulating multiple inflammatory protein systems simultaneously. Disease focus includes ocular inflammatory diseases (dry eye disease, allergic conjunctivitis, age-related macular degeneration), systemic immune-mediated diseases (atopic dermatitis, psoriasis, asthma), and rare retinal diseases.
Targets: RASP, reactive aldehyde species
Discontinued (2)
- ADX-629 — undisclosed · completed proof-of-concept testing; no longer in development aside from potential investigator-sponsored trials in Sjögren-Larsson Syndrome
- ADX-2191 — Proliferative Vitreoretinopathy · Company ceased development of the Helio Product Candidate for the treatment of proliferative vitreoretinopathy during year ended December 31, 2024
Biotech Distilled coverage (5)
- 2026-05-08 UPDATE: Aldeyra Therapeutics (ALDX) - The Cash Floor Just Got Lower 🔒 Paid
- 2026-05-02 UPDATE: Aldeyra Therapeutics (ALDX) - Reading the FDA’s Margin Notes 🔒 Paid
- 2026-03-21 UPDATE: Aldeyra Therapeutics (ALDX) - The Bottom Falls Out 🔒 Paid
- 2026-02-28 UPDATE: Aldeyra Therapeutics (ALDX) - The Final Countdown to PDUFA 🔒 Paid
- 2025-12-17 BONUS: Aldeyra Therapeutics (ALDX): Scientific Due Diligence for Reproxalap and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.